Amyotrophic lateral sclerosis (ALS) is a rapidly progressive neurodegenerative disorder
affecting upper and lower motor neurons, with death resulting mainly from respiratory failure …

Objective To compare the effect of riluzole on median survival in population studies of
patients with amyotrophic lateral sclerosis (ALS) with that observed in clinical trials …

The care and management of patients with ALS should always be patient focused, with
attention to holistic and emotional aspects of well-being. It is the patient who ultimately …

Amyotrophic Lateral Sclerosis (ALS) is a neurodegenerative disorder with an unknown
etiology and no effective treatment, and is characterized by large phenotypic heterogeneity …

Increased incidence rates of amyotrophic lateral sclerosis (ALS) have been recently
reported across various Western countries, although geographic and temporal variations in …

Multidisciplinary care (MDC) has been the most recommended approach for symptom
management in amyotrophic lateral sclerosis (ALS) but there is conflicting evidence about its …

Abstract Introduction/Aims Riluzole improves survival in amyotrophic lateral sclerosis (ALS),
but optimal time and duration of treatment are unknown. The aim of this study was to …

Abstract Objective To employ Artificial Intelligence to model, predict and simulate the
amyotrophic lateral sclerosis (ALS) progression over time in terms of variable interactions …

Background Oral tauroursodeoxycholic acid (TUDCA) is a commercial drug currently tested
in patients with amyotrophic lateral sclerosis (ALS) both singly and combined with sodium …

Background: Amyotrophic lateral sclerosis (ALS) is a progressive fatal disease with a
varying range of clinical characteristics. Objective: To describe the clinical characteristics in …